SEC Comment Letter 0000000000-24-013253 to Mereo BioPharma Group plc (MREO) (CIK 0001719714) (MREO)
Mereo BioPharma Group plc (MREO) (CIK 0001719714)
Date: Dec. 2, 2024 · CIK: 0001719714 · Accession: 0000000000-24-013253
AI Filing Summary & Sentiment
File numbers found in text: 333-283439
Letter
December 2, 2024 Denise Scots-Knight Chief Executive Officer Mereo BioPharma Group plc One Cavendish Place, 4th Floor London, W1G 0QF United Kingdom Re:Mereo BioPharma Group plc Registration Statement on Form S-3 Filed November 25, 2024 File No. 333-283439 Dear Denise Scots-Knight: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:David Bakst, Esq.
Show Raw Text
December 2, 2024
Denise Scots-Knight
Chief Executive Officer
Mereo BioPharma Group plc
One Cavendish Place, 4th Floor
London, W1G 0QF United Kingdom
Re:Mereo BioPharma Group plc
Registration Statement on Form S-3
Filed November 25, 2024
File No. 333-283439
Dear Denise Scots-Knight:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:David Bakst, Esq.